Connected Thinking

Leading Voices

Latest News

Addressing Disparities in Cancer: What Industry and Clinicians Can Do to Collaborate Effectively

As key players in the oncology community, industry and clinicians have the power to make tangible progress on key aspects on disparities, according to panelists at Survivornet’s 2022 Close the Gap conference. 

Learn More

‘This is a Period of Rapid Progress:’ Dr. Giovanni Caforio of Bristol-Myers Squibb on the Revolution in Immunotherapy Drugs for Treating Advanced Cancers

Every once in a while, we think there’s some value in giving the SN Connect audience a little taste of some very key players in the oncology system. A while back, SurvivorNet had the chance to sit down with Dr. Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb (BMS).

Learn More

ASCO: Study Finds Ibrutinib Can Improve Outcomes In Some Newly Diagnosed Patients With Mantle Cell Lymphoma

The trial showed improvement in progression-free survival for patients with newly diagnosed mantle cell lymphoma.

Learn More

ASCO: New Study Provides Hope For Patients With HER2 ‘Low’ Breast Cancer

HER2 “low” may become a new commonly classified subtype of breast cancer.

Learn More

ASCO: Updated Guidelines on Biomarkers for Early-Stage Breast Cancer

The new guidelines now recommend the use of Breast Cancer Index (BCI) to assess the risk of breast cancer recurrence in some patients.

Learn More

ASCO: Study Indicates Panitumumab Works Best For Patients With One Type Of Metastatic Colorectal Cancer

A new trial is the first to compare the effectiveness of different targeted drug therapies as part of chemo treatments for a certain kind of metastatic colorectal cancer (left sided).

Learn More

Treating Multiple Myeloma in the Second Line: Which Option Should You Choose?

After first-line multiple myeloma treatment, which strategy is best for second-line therapy?

Learn More

Bispecific Antibodies Challenge CAR T-Cell Therapy as Multiple Myeloma Treatment Contender

The latest buzzword in multiple myeloma is bispecifics. This off-the-shelf treatment is proving to be an attractive option for patients who can't wait for CAR T-cell therapy.

Learn More